Hussein Shaimaa, Khanna Pooja, Yunus Neha, Gatza Michael L
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Department of Radiation Oncology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08903, USA.
Cancers (Basel). 2021 Sep 26;13(19):4808. doi: 10.3390/cancers13194808.
Metabolic reprogramming enables cancer cells to adapt to the changing microenvironment in order to maintain metabolic energy and to provide the necessary biological macromolecules required for cell growth and tumor progression. While changes in tumor metabolism have been long recognized as a hallmark of cancer, recent advances have begun to delineate the mechanisms that modulate metabolic pathways and the consequence of altered signaling on tumorigenesis. This is particularly evident in hormone receptor positive (HR+) breast cancers which account for approximately 70% of breast cancer cases. Emerging evidence indicates that HR+ breast tumors are dependent on multiple metabolic processes for tumor progression, metastasis, and therapeutic resistance and that changes in metabolic programs are driven, in part, by a number of key nuclear receptors including hormone-dependent signaling. In this review, we discuss the mechanisms and impact of hormone receptor mediated metabolic reprogramming on HR+ breast cancer genesis and progression as well as the therapeutic implications of these metabolic processes in this disease.
代谢重编程使癌细胞能够适应不断变化的微环境，以维持代谢能量，并提供细胞生长和肿瘤进展所需的必要生物大分子。虽然肿瘤代谢的变化长期以来一直被认为是癌症的一个标志，但最近的进展已开始阐明调节代谢途径的机制以及信号改变对肿瘤发生的影响。这在占乳腺癌病例约70%的激素受体阳性（HR+）乳腺癌中尤为明显。新出现的证据表明，HR+乳腺肿瘤在肿瘤进展、转移和治疗耐药方面依赖多种代谢过程，并且代谢程序的变化部分是由包括激素依赖性信号传导在内的一些关键核受体驱动的。在本综述中，我们讨论了激素受体介导的代谢重编程对HR+乳腺癌发生和进展的机制及影响，以及这些代谢过程在该疾病中的治疗意义。
